The Role of Glucocorticoids in the Management of COVID-19

Vasileia Ismini Alexaki; Holger Henneicke

doi:10.1055/a-1300-2550

Hormone and Metabolic Research, Table of Contents

CC BY-NC-ND 4.0 · Horm Metab Res 2021; 53(01): 9-15
DOI: 10.1055/a-1300-2550

Review

The Role of Glucocorticoids in the Management of COVID-19

Authors

Vasileia Ismini Alexaki

¹Institute for Clinical Chemistry and Laboratory Medicine, Faculty of Medicine and University Clinic Carl Gustav Carus, TU Dresden, Dresden, Germany
Holger Henneicke

²Center for Regenerative Therapies Dresden, TU Dresden, Dresden, Germany

³Department of Medicine III & Center for Healthy Aging, University Clinic Carl Gustav Carus, TU Dresden, Dresden, Germany

Abstract

Coronavirus disease 2019 (COVID-19), caused by an infection with the novel coronavirus SARS-CoV-2, has resulted in a global pandemic and poses an emergency to public health systems worldwide. COVID-19 is highly infectious and is characterized by an acute respiratory illness that varies from mild flu-like symptoms to the life-threatening acute respiratory distress syndrome (ARDS). As such, there is an urgent need for the development of new therapeutic strategies, which combat the high mortality in severely ill COVID-19 patients. Glucocorticoids are a frontline treatment for a diverse range of inflammatory diseases. Due to their immunosuppressive functions, the use of glucocorticoids in the treatment of COVID-19 patients was initially regarded with caution. However, recent studies concluded that the initiation of systemic glucocorticoids in patients suffering from severe and critical COVID-19 is associated with lower mortality. Herein we review the anti-inflammatory effects of glucocorticoids and discuss emerging issues in their clinical use in the context of COVID-19.

Key words

glucocorticoids inflammation COVID-19

Full Text

References

References
1 Chen N, Zhou M, Dong X. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020; 395: 507-513
2 Lu R, Zhao X, Li J. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020; 395: 565-574
3 Fan E, Beitler JR, Brochard L. et al. COVID-19-associated acute respiratory distress syndrome: Is a different approach to management warranted?. Lancet Respir Med 2020; 8: 816-821
4 Hussman JP. Cellular and Molecular Pathways of COVID-19 and potential points of therapeutic intervention. Front Pharmacol 2020; 11: 1169
5 Shah A, Donovan K, McHugh A. et al. Thrombotic and haemorrhagic complications in critically ill patients with COVID-19: A multicentre observational study. Crit Care 2020; 24: 561
6 Group WHOREAfC-TW Sterne JAC, Murthy S. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: A Meta-analysis. JAMA 2020; 324: 1330-1341
7 Timmermans S, Souffriau J, Libert C. A General Introduction to Glucocorticoid Biology. Front Immunol 2019; 10: 1545
8 Cain DW, Cidlowski JA. Immune regulation by glucocorticoids. Nat Rev Immunol 2017; 17: 233-247
9 Kanczkowski W, Alexaki VI, Tran N. et al. Hypothalamo-pituitary and immune-dependent adrenal regulation during systemic inflammation. Proc Natl Acad Sci USA 2013; 110: 14801-14806
10 Vandewalle J, Libert C. Glucocorticoids in Sepsis: To Be or Not to Be. Front Immunol 2020; 11: 1318
11 Petta I, Dejager L, Ballegeer M. et al. The interactome of the glucocorticoid receptor and its influence on the actions of glucocorticoids in combatting inflammatory and infectious diseases. Microbiol Mol Biol Rev 2016; 80: 495-522
12 Lim HW, Uhlenhaut NH, Rauch A. et al. Genomic redistribution of GR monomers and dimers mediates transcriptional response to exogenous glucocorticoid in vivo. Genome Res 2015; 25: 836-844
13 Hudson WH, Youn C, Ortlund EA. The structural basis of direct glucocorticoid-mediated transrepression. Nat Struct Mol Biol 2013; 20: 53-58
14 Widen C, Gustafsson JA, Wikstrom AC. Cytosolic glucocorticoid receptor interaction with nuclear factor-kappa B proteins in rat liver cells. Biochem J 2003; 373: 211-220
15 Berrebi D, Bruscoli S, Cohen N. Synthesis of glucocorticoid-induced leucine zipper (GILZ) by macrophages: an anti-inflammatory and immunosuppressive mechanism shared by glucocorticoids and IL-10. Blood 2003; 101: 729-738
16 Panettieri RA, Schaafsma D, Amrani Y. et al. Non-genomic effects of glucocorticoids: An updated view. Trends Pharmacol Sci 2019; 40: 38-49
17 Lowenberg M, Verhaar AP, Bilderbeek J. et al. Glucocorticoids cause rapid dissociation of a T-cell-receptor-associated protein complex containing LCK and FYN 2006; 7: 1023-1029
18 Jiang CL, Liu L, Tasker JG. Why do we need nongenomic glucocorticoid mechanisms?. Front Neuroendocrinol 2014; 35: 72-75
19 Busillo JM, Cidlowski JA. The five Rs of glucocorticoid action during inflammation: Ready, reinforce, repress, resolve, and restore. Trends Endocrinol Metab 2013; 24: 109-119
20 Lim HY, Muller N, Herold MJ. et al. Glucocorticoids exert opposing effects on macrophage function dependent on their concentration. Immunology 2007; 122: 47-53
21 Dhabhar FS, McEwen BS. Enhancing versus suppressive effects of stress hormones on skin immune function. Proc Natl Acad Sci USA 1999; 96: 1059-1064
22 Quatrini L, Ugolini S. New insights into the cell- and tissue-specificity of glucocorticoid actions. Cell Mol Immunol 2020; 1-10
23 Miyata M, Lee JY, Susuki-Miyata S. et al. Glucocorticoids suppress inflammation via the upregulation of negative regulator IRAK-M. Nat Commun 2015; 6: 6062
24 Bhattacharyya S, Brown DE, Brewer JA. et al. Macrophage glucocorticoid receptors regulate Toll-like receptor 4-mediated inflammatory responses by selective inhibition of p38 MAP kinase. Blood 2007; 109: 4313-4319
25 Visser J, van Boxel-Dezaire A, Methorst D. et al. Differential regulation of interleukin-10 (IL-10) and IL-12 by glucocorticoids in vitro. Blood 1998; 91: 4255-4264
26 Lee SH, Soyoola E, Chanmugam P. et al. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J Biol Chem 1992; 267: 25934-25938
27 Yang N, Zhang W, Shi XM. Glucocorticoid-induced leucine zipper (GILZ) mediates glucocorticoid action and inhibits inflammatory cytokine-induced COX-2 expression. J Cell Biochem 2008; 103: 1760-1771
28 Mitroulis I, Alexaki VI, Kourtzelis I. et al. Leukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory disease. Pharmacol Ther 2015; 147: 123-135
29 Zielinska KA, Van Moortel L, Opdenakker G. et al. Endothelial response to glucocorticoids in inflammatory diseases. Front Immunol 2016; 7: 592
30 Ehrchen J, Steinmuller L, Barczyk K. et al. Glucocorticoids induce differentiation of a specifically activated, anti-inflammatory subtype of human monocytes. Blood 2007; 109: 1265-1274
31 Mozo L, Suarez A, Gutierrez C. Glucocorticoids up-regulate constitutive interleukin-10 production by human monocytes. Clin Exp Allergy 2004; 34: 406-412
32 Tu GW, Shi Y, Zheng YJ. et al. Glucocorticoid attenuates acute lung injury through induction of type 2 macrophage. J Transl Med 2017; 15: 181
33 Meers GK, Bohnenberger H, Reichardt HM. et al. Impaired resolution of DSS-induced colitis in mice lacking the glucocorticoid receptor in myeloid cells. PLoS One 2018; 13: e0190846
34 Vallelian F, Schaer CA, Kaempfer T. et al. Glucocorticoid treatment skews human monocyte differentiation into a hemoglobin-clearance phenotype with enhanced heme-iron recycling and antioxidant capacity. Blood 2010; 116: 5347-5356
35 van der Goes A, Hoekstra K, van den Berg TK. et al. Dexamethasone promotes phagocytosis and bacterial killing by human monocytes/macrophages in vitro. J Leukoc Biol 2000; 67: 801-807
36 Cao Y, Bender IK, Konstantinidis AK. et al. Glucocorticoid receptor translational isoforms underlie maturational stage-specific glucocorticoid sensitivities of dendritic cells in mice and humans. Blood 2013; 121: 1553-1562
37 Kim KD, Choe YK, Choe IS. et al. Inhibition of glucocorticoid-mediated, caspase-independent dendritic cell death by CD40 activation. J Leukoc Biol 2001; 69: 426-434
38 Wang D, Muller N, McPherson KG. et al. Glucocorticoids engage different signal transduction pathways to induce apoptosis in thymocytes and mature T cells. J Immunol 2006; 176: 1695-1702
39 Lowenberg M, Verhaar AP, van den Brink GR. et al. Glucocorticoid signaling: a nongenomic mechanism for T-cell immunosuppression. Trends Mol Med 2007; 13: 158-163
40 Bereshchenko O, Coppo M, Bruscoli S. et al. GILZ promotes production of peripherally induced Treg cells and mediates the crosstalk between glucocorticoids and TGF-beta signaling. Cell Rep 2014; 7: 464-475
41 Galon J, Franchimont D, Hiroi N. et al. Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. FASEB J 2002; 16: 61-71
42 Alan I, Alan B. Side effects of glucocorticoids. Pharmacokinetics and adverse effects of drugs - mechanisms and risks Factors 2017;
43 Huscher D, Thiele K, Gromnica-Ihle E. et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis 2009; 68: 1119-1124
44 Nicolaides NC, Pavlaki AN, Maria Alexandra MA. et al. Endotext. South Dartmouth, MA: 2000
45 Hoffmann M, Kleine-Weber H, Schroeder S. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and Is blocked by a clinically proven protease inhibitor. Cell 2020; 181: 271-280 e278
46 Shereen MA, Khan S, Kazmi A. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. J Adv Res 2020; 24: 91-98
47 Huang C, Wang Y, Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497-506
48 Qin C, Zhou L, Hu Z. et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis 2020; 71: 762-768
49 Blanco-Melo D, Nilsson-Payant BE, Liu WC. et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell 2020; 181: 1036-1045 e1039
50 Fox SE, Akmatbekov A, Harbert JL. et al. Pulmonary and cardiac pathology in African American patients with COVID-19: An autopsy series from New Orleans. Lancet. Respir Med 2020; 8: 681-686
51 Polycarpou A, Howard M, Farrar CA. et al. Rationale for targeting complement in COVID-19. EMBO Mol Med 2020; 12: e12642
52 Gralinski LE, Sheahan TP, Morrison TE. et al. Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis. mBio 2018; 9: e01753-18
53 Risitano AM, Mastellos DC, Huber-Lang M. et al. Complement as a target in COVID-19?. Nat Rev Immunol 2020; 20: 343-344
54 Java A, Apicelli AJ, Liszewski MK. et al. The complement system in COVID-19: friend and foe?. JCI Insight 2020; 5: e140711
55 Risitano AM, Mastellos DC, Huber-Lang M. et al. Author Correction: Complement as a target in COVID-19?. Nat Rev Immunol 2020; 20: 448
56 Xu Z, Shi L, Wang Y. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet. Respir Med 2020; 8: 420-422
57 Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clin Chim Acta 2020; 506: 145-148
58 Liu F, Ji C, Luo J. et al. Clinical characteristics and corticosteroids application of different clinical types in patients with corona virus disease 2019. Sci Rep 2020; 10: 13689
59 Selvaraj V, Dapaah-Afriyie K, Finn A. et al. Short-Term Dexamethasone in Sars-CoV-2 Patients. R I Med J (2013) 2020; 103: 39-43
60 Bellani G, Laffey JG, Pham T. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA 2016; 315: 788-800
61 Acute Respiratory Distress Syndrome N, Brower RG, Matthay MA. et al. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000; 342: 1301-1308
62 Guerin C, Reignier J, Richard JC. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med 2013; 368: 2159-2168
63 Agarwal R, Nath A, Aggarwal AN. et al. Do glucocorticoids decrease mortality in acute respiratory distress syndrome? A meta-analysis. Respirology 2007; 12: 585-590
64 Meduri GU, Marik PE, Chrousos GP. et al. Steroid treatment in ARDS: a critical appraisal of the ARDS network trial and the recent literature. Intensive Care Med 2008; 34: 61-69
65 Zayed Y, Barbarawi M, Ismail E. et al. Use of glucocorticoids in patients with acute respiratory distress syndrome: A meta-analysis and trial sequential analysis. J Intensive Care 2020; 8: 43
66 Zhao Q, Shi JX, Hu R. et al. Effect of glucocorticoids on mortality in patients with acute respiratory distress syndrome: A meta-analysis. Exp Ther Med 2019; 18: 4913-4920
67 Arabi YM, Mandourah Y, Al-Hameed F. et al. Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome. Am J Respir Crit Care Med 2018; 197: 757-767
68 Lansbury LE, Rodrigo C, Leonardi-Bee J. et al. Corticosteroids as adjunctive therapy in the treatment of influenza: An updated cochrane systematic review and meta-analysis. Crit Care Med 2020; 48: e98-e106
69 Rostaing L, Malvezzi P. Steroid-based therapy and risk of infectious complications. PLoS Med 2016; 13: e1002025
70 Fardet L, Petersen I, Nazareth I. Common infections in patients prescribed systemic glucocorticoids in primary care: a population-based cohort study. PLoS Med 2016; 13: e1002024
71 Normand ST. The RECOVERY Platform. N Engl J Med 2020;
72 Group RC, Horby P, Lim WS. et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med 2020;
73 Critchley JA, Carey IM, Harris T. et al. Glycemic control and risk of infections among people with type 1 or type 2 diabetes in a large primary care cohort study. Diabetes Care 2018; 41: 2127-2135
74 Rao Kondapally Seshasai S, Kaptoge S, Thompson A. et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011; 364: 829-841
75 Yang JK, Feng Y, Yuan MY. et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med 2006; 23: 623-628
76 Alqahtani FY, Aleanizy FS, Ali El Hadi Mohamed R. et al. Prevalence of comorbidities in cases of Middle East respiratory syndrome coronavirus: a retrospective study. Epidemiol Infect 2018; 147: 1-5
77 Zhou F, Yu T, Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020; 395: 1054-1062
78 Barron E, Bakhai C, Kar P. et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: A whole-population study. Lancet Diabetes Endocrinol 2020; 8: 813-822
79 Holman N, Knighton P, Kar P. et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: A population-based cohort study. Lancet Diabetes Endocrinol 2020; 8: 823-833
80 Zhu L, She ZG, Cheng X. et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab 2020; 31: 1068-1077 e1063
81 Kalligeros M, Shehadeh F, Mylona EK. et al. Association of obesity with disease severity among patients with coronavirus disease 2019. Obesity (Silver Spring) 2020; 28: 1200-1204
82 Hamer M, Gale CR, Kivimaki M. et al. Overweight, obesity, and risk of hospitalization for COVID-19: A community-based cohort study of adults in the United Kingdom. Proc Natl Acad Sci USA 2020; 117: 21011-21013
83 Bornstein SR, Rubino F, Khunti K. et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol 2020; 8: 546-550
84 Erener S. Diabetes, infection risk and COVID-19. Mol Metab 2020; 39: 101044
85 Feldman-Billard S, Lissak B, Kassaei R. et al. Short-term tolerance of pulse methylprednisolone therapy in patients with diabetes mellitus. Ophthalmology 2005; 112: 511-515
86 Reynolds RM, Labad J, Sears AV. et al. Glucocorticoid treatment and impaired mood, memory and metabolism in people with diabetes: The Edinburgh Type 2 Diabetes Study. Eur J Endocrinol 2012; 166: 861-868
87 Fardet L, Flahault A, Kettaneh A. et al. Corticosteroid-induced clinical adverse events: frequency, risk factors and patient's opinion. Br J Dermatol 2007; 157: 142-148
88 Sato A, Funder JW, Okubo M. et al. Glucocorticoid-induced hypertension in the elderly. Relation to serum calcium and family history of essential hypertension. Am J Hypertens 1995; 8: 823-828
89 Curtis JR, Westfall AO. Allison. et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 2006; 55: 420-426
90 Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004; 141: 764-770
91 Souverein PC, Berard A, Van Staa TP. et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart 2004; 90: 859-865